Brief Title
The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study
Official Title
The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study
Brief Summary
To assess the safety and clinical performance of the CoreValve™ Evolut R™ System.
Detailed Description
The study objectives are to assess the safety and clinical performance of the CoreValve™
Evolut R™ System in patients with severe symptomatic aortic stenosis who are considered at
high through extreme risk for surgical aortic valve replacement. These objectives will be
accomplished by a prospective clinical study involving up to 60 implanted subjects among up
to six study centers.
Study Type
Interventional
Primary Outcome
All-cause Mortality Rate at 30 Days
Secondary Outcome
VARC II Combined Safety Endpoint at 30 Days
Condition
Aortic Stenosis
Intervention
The CoreValve™ Evolut R TAV™ system
Study Arms / Comparison Groups
The CoreValve™ Evolut R TAV™ system
Description: CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
60
Start Date
October 2013
Completion Date
October 2016
Primary Completion Date
August 2014
Eligibility Criteria
Inclusion Criteria:
1. Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve
area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or
maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.
2. Estimated 30 day mortality risk of > 15% by study center Heart Team assessment,33 OR
at least two cardiovascular surgeons from the study center deny surgery because of
prohibitive operative risk, estimated to be a combined >50% risk of irreversible
mortality or morbidity.
3. Symptoms of aortic stenosis, and NYHA Functional Class II or greater.
4. The subject meets the legal minimum age to provide informed consent based on local
regulatory requirements, and has provided written informed consent as approved by the
EC/IRB of the respective clinical site.
5. The subject and the treating physician agree that the subject will return for all
required post-procedure follow-up visits.
Exclusion Criteria:
Clinical exclusion criteria:
6. Subject has been offered SAVR but has declined.
7. Any condition considered a contraindication for placement of a bioprosthetic valve
(e.g. subject is indicated for mechanical prosthetic valve).
8. Known hypersensitivity or contraindication to Nitinol.
9. Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), thrombocytopenia (platelet
count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or
hypercoagulable states.
10. Untreated clinically significant coronary artery disease requiring revascularization.
11. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF)
<20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.
12. End stage renal disease requiring chronic dialysis of creatinine clearance < 20
cc/min.
13. Ongoing sepsis, including active endocarditis.
14. Any condition considered a contraindication to extracorporeal assistance.
15. Any percutaneous coronary or peripheral interventional procedure with a bare metal
stent performed within 30 days prior to Heart Team assessment, or within six months
prior to Heart Team assessment for procedures with a drug eluting stents.
16. Symptomatic carotid or vertebral artery disease or successful treatment of carotid
stenosis within eight weeks of Heart Team Assessment .
17. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
mechanical hemodynamic support.
18. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or
transient ischemic attack (TIA).
19. Gastrointestinal (GI) bleeding that would preclude anticoagulation.
20. Subject refuses a blood transfusion.
21. Severe dementia (resulting in either inability to provide informed consent for the
study/procedure, prevents independent lifestyle outside of a chronic care facility, or
will fundamentally complicate rehabilitation from the procedure or compliance with
follow-up visits).
22. Estimated life expectancy of less than 12 months due to associated non-cardiac
co-morbid conditions.
23. Other medical, social, or psychological conditions that in the opinion of the
Investigator precludes the subject from appropriate consent or adherence to the
protocol required follow-ups exams.
24. Currently participating in an investigational drug or another device study (excluding
registries).
25. Evidence of an acute myocardial infarction ≤30 days before the index procedure.
26. Need for emergency surgery for any reason.
27. Liver failure (Child-C).
28. Subject is pregnant or breast feeding.
Anatomical exclusion criteria:
29. Pre-existing prosthetic heart valve in any position.
30. Mixed aortic valve disease (aortic stenosis with moderate or severe aortic
regurgitation).
31. Severe mitral regurgitation.
32. Severe tricuspid regurgitation.
33. Moderate or severe mitral stenosis.
34. Hypertrophic obstructive cardiomyopathy.
35. Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac
mass thrombus or vegetation.
36. Congenital bicuspid or unicuspid valve verified by echocardiography.
Gender
All
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
Eric Vang, PhD, ,
Location Countries
Australia
Location Countries
Australia
Administrative Informations
NCT ID
NCT01876420
Organization ID
MDT10093773DOC
Responsible Party
Sponsor
Study Sponsor
Medtronic Cardiovascular
Collaborators
Medtronic
Study Sponsor
Eric Vang, PhD, Study Director, Director Clinical Research Structural Heart
Verification Date
August 2018